stoxline Quote Chart Rank Option Currency Glossary
Novo Nordisk A/S (NVO)
133.45  0.77 (0.58%)    05-30 15:16
Open: 133.89
High: 134.58
Volume: 1,856,427
Pre. Close: 132.68
Low: 133.0238
Market Cap: 593,697(M)
Technical analysis
2024-05-30 2:45:58 PM
Short term     
Mid term     
Targets 6-month :  160.27 1-year :  187.19
Resists First :  137.22 Second :  160.27
Pivot price 133.04
Supports First :  127.37 Second :  121.29
MAs MA(5) :  134.32 MA(20) :  131.06
MA(100) :  123.55 MA(250) :  104.58
MACD MACD :  1.9 Signal :  1.9
%K %D K(14,3) :  63.2 D(3) :  73.7
RSI RSI(14): 56.1
52-week High :  138.27 Low :  75.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVO ] has closed below upper band by 47.3%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 133.2 - 134.09 134.09 - 134.83
Low: 130.32 - 131.2 131.2 - 131.94
Close: 131.38 - 132.82 132.82 - 134.01
Company Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headline News

Thu, 30 May 2024
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs - - Benzinga

Tue, 28 May 2024
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System - Yahoo Canada Finance

Tue, 28 May 2024
Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Tue, 28 May 2024
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Yahoo Finance

Tue, 28 May 2024
Novo Nordisk Launches Major Share Buyback - - TipRanks

Tue, 28 May 2024
Novo Nordisk: The Market Is Right, Don't Fight Against It (NYSE:NVO) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 4,450 (M)
Shares Float 3,190 (M)
Held by Insiders 0 (%)
Held by Institutions 9.3 (%)
Shares Short 3,640 (K)
Shares Short P.Month 2,830 (K)
Stock Financials
EPS 2.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 22.18
Profit Margin 36.5 %
Operating Margin 48.7 %
Return on Assets (ttm) 25.2 %
Return on Equity (ttm) 99.8 %
Qtrly Rev. Growth 22.5 %
Gross Profit (p.s.) 0
Sales Per Share 54.88
EBITDA (p.s.) 26.48
Qtrly Earnings Growth 29.3 %
Operating Cash Flow 93,410 (M)
Levered Free Cash Flow 40,240 (M)
Stock Valuations
PE Ratio 46.59
PEG Ratio 92.1
Price to Book value 6
Price to Sales 2.42
Price to Cash Flow 6.34
Stock Dividends
Dividend 0.93
Forward Dividend 0
Dividend Yield 0.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android